Journal: Pharmacological research

Article Title: Endosomal escape of nucleic acids from extracellular vesicles mediates functional therapeutic delivery.

doi: 10.1016/j.phrs.2023.106665

Figure Lengend Snippet: Fig. 5. Therapeutic ASOs delivered by RBCEVs suppress tumor growth in vivo. a Outline of AML xenografting and ASO delivery in NSGS mice. b Representative bioluminescent images of NSGS mice implanted with MOLM13-luciferase-GFP cells followed by BCL2 ASO-loaded RBCEVs treatment. Pseudocolors indicate bioluminescent intensity (photon/second). c Leukemia progression in mice was quantified using the average bioluminescent signals following treatment with PBS (n = 5 mice), and RBCEVs loaded with NC ASO or BCL2 ASOs (n = 6 mice). d Percentage of GFP-positive leukemia cells in the bone marrow, liver, and spleen of mice treated with PBS, NC ASO-, or BCL2 ASO-loaded RBCEVs. e The average weight of the leukemia xenograft mice treated with PBS, NC ASO-, or BCL2 ASO-loaded RBCEVs. All bar graphs represent mean ± SEM. ns – not significant, * P < 0.05 and * * P < 0.01 determined by Student’s one-tailed t-test and two-way ANOVA with Tukey post-hoc test (c).

Article Snippet: To generate xenografted murine model for acute myeloid leukemia, NSGS male mice of 8–9 weeks old (24.6 ± 0.65 g) were pre-conditioned with Busulfan (Santa Cruz, 20 mg/kg) by tail vein injection.

Techniques: In Vivo, Luciferase, One-tailed Test